Trovagene says PCM technology yields significantly greater detection sensitivity
Trovagene announced that the use of their Precision Cancer Monitoring technology for both urine and plasma EGFR mutation testing yielded significantly greater detection sensitivity than tissue testing alone. Data will be presented at the 17th World Conference on Lung Cancer, December 4-7 in Vienna, Austria. Trovagene's abstract entitled, A Highly Sensitive Next Generation Sequencing Platform for Detection of NSCLC EGFR T790M in Urine and Plasma, was selected for an oral presentation. This presentation will include data showing a 95% overall detection rate of EGFR T790M by combined urine and plasma versus 83% detection by tissue testing. Additionally, the detection rate in intrathoracic lung cancer disease, in the absence of distant metastases, was an unprecedented 93%. This data further validates the high sensitivity of Trovagene's, Trovera urine and blood liquid biopsy test to identify the EGFR T790M resistance mutation in patients with late-stage non-small cell lung cancer progressing on 1st or 2nd generation TKIs. Two additional abstracts, one a case series, focus on recent work demonstrating that EGFR ctDNA can serve as an early indicator of therapeutic response, providing valuable information particularly in the setting of late-stage patients treated with experimental therapeutics or in patients progressing on therapy. The dynamic changes in ctDNA EGFR systemic load observed in this case series is consistent with previous findings. A fourth poster presentation will feature cost of care analysis data demonstrating the value of a urine testing strategy as a dominant care pathway compared to a tissue testing strategy by saving costs and improving progression-free and overall survival for patients with non-small cell lung cancer.